Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teva Pharmaceutical Industries Limited filings document material events, operating and financial results, capital-structure matters, governance, and shareholder voting for the Israel-based pharmaceutical issuer. Its 8-K reports include results announcements, conference-related outlook disclosures, and material definitive agreements, including amendments to a senior unsecured sustainability-linked revolving credit facility.
Teva's proxy materials cover annual meeting procedures, shareholder proposals, governance matters, and annual consolidated financial statements. The filing record also identifies the company's American Depositary Shares, each representing one ordinary share, as securities registered for trading under TEVA on the New York Stock Exchange.
Teva Pharmaceutical Industries executive Matthew Shields, EVP of Global Operations, reported an open-market sale of 9,989 Ordinary Shares. The shares were sold at an average price of $32.1901 per share, and his directly held Ordinary Share position is reported as 0 shares following the transaction. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA Form 144 notice reports a proposed sale of Ordinary Shares and a recent sale by an affiliated holder. The filing lists a planned disposition through Citigroup Global Markets and records a sale by Matthew Shields of 16,195 shares for $532,329.65 on 06/03/2026. The securities are identified as Ordinary Shares with an associated identifier 9989.
TEVA Form 144 notice reports a proposed sale of Ordinary Shares and a recent sale by an affiliated holder. The filing lists a planned disposition through Citigroup Global Markets and records a sale by Matthew Shields of 16,195 shares for $532,329.65 on 06/03/2026. The securities are identified as Ordinary Shares with an associated identifier 9989.
TEVA Form 144 notice reports a proposed sale of Ordinary Shares and a recent sale by an affiliated holder. The filing lists a planned disposition through Citigroup Global Markets and records a sale by Matthew Shields of 16,195 shares for $532,329.65 on 06/03/2026. The securities are identified as Ordinary Shares with an associated identifier 9989.
Teva Pharmaceutical Industries EVP and CFO Eliyahu Sharon Kalif sold 106,563 Ordinary Shares in an open-market transaction on June 11, 2026 at a weighted average price of $34.0954 per share. After the sale, he directly holds 65,621 Ordinary Shares.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, indicating it was scheduled in advance. The filing notes that the price reflects a weighted average from multiple trades between $33.985 and $34.25 per share. Each Ordinary Share may also be represented by one American Depositary Share.
Teva Pharmaceutical Industries submitted a Form 144 notice reporting proposed sales of ordinary shares tied to rollover/compensation transactions and prior dispositions. The filing lists multiple lot sizes dated 03/03/2026 and 03/04/2026, including quantities of 24,900, 33,512, and 23,251 shares. The excerpt also shows 153,251 shares sold during the past three months on 05/14/2026 for $5,457,368.64. The filing names Citigroup Global Markets as a broker and identifies the transactions as compensation ordinary shares or shares from rollover.
Teva Pharmaceutical Industries director Sol J. Barer exercised 21,739 restricted share units into ordinary shares. The RSUs were granted on June 5, 2025 and vested on June 5, 2026, resulting in delivery of 21,739 ordinary shares at a stated price of $0.00 per share.
Following this vesting and conversion, Barer directly holds 448,011 ordinary shares. The transaction reflects a compensation-related derivative exercise with no reported open-market buying or selling. The ordinary shares may also be represented by American Depositary Shares, each currently equal to one ordinary share.
Teva Pharmaceutical Industries director Chen Lichtenstein exercised 14,492 restricted share units into ordinary shares, increasing his direct stake to 19,296 shares. The units were granted on June 5, 2025 and vested on June 5, 2026, and each unit settled into one ordinary share at no cash cost to him.
The ordinary shares may be held directly or represented by American Depositary Shares, each currently equal to one ordinary share. The filing reflects a compensation-related equity vesting and exercise, not an open-market purchase or sale.
TEVA Pharmaceutical Industries director Rosemary A. Crane exercised 14,492 restricted share units into ordinary shares. The Form 4 shows she acquired 14,492 ordinary shares on June 5, 2026 through the conversion of vested restricted share units at a stated price of $0.00 per share.
Following this transaction, Crane directly holds 127,739 ordinary shares. The derivative position associated with these 14,492 restricted share units is now fully settled, with no remaining units from this grant. The footnotes state that each restricted share unit represented a contingent right to receive one ordinary share or its cash value and that the units were granted on June 5, 2025 and vested on June 5, 2026.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Amir Elstein exercised restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at a stated price of $0.00 per share.
After this non-cash equity compensation event, Elstein directly held 2,118,455 ordinary shares. Each restricted share unit provided a contingent right to receive one ordinary share or, at the company committee’s option, the cash value of one ordinary share. No open-market buy or sell transaction was reported in this filing.
Teva Pharmaceutical Industries director Gerald M. Lieberman exercised restricted share units into ordinary shares. On June 5, 2026, he acquired 14,492 ordinary shares at a stated price of $0.00 per share through the vesting and conversion of restricted share units granted on June 5, 2025.
Following this transaction, he directly holds 130,149 ordinary shares. The footnotes note that each restricted share unit entitled him, at settlement, to receive one ordinary share or the cash value of one ordinary share, and that ordinary shares may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries director Nisen Perry exercised previously granted restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were settled into 14,492 ordinary shares, bringing Perry’s direct holdings to 119,807 ordinary shares.